Article
Bristol Myers on track for 3rd new drug launch of 2022 with latest deucravacitinib data
Rating:
0.0
Views:
73
Likes:
1
Library:
1
Bristol Myers Squibb just released new two-year deucravacitinib data showing lasting efficacy for patients with moderate to severe plaque psoriasis. | Bristol Myers Squibb just released new two-year deucravacitinib data showing lasting efficacy and safety for patients with moderate to severe plaque psoriasis. The company anticipates launching the drug in September, when it would go up against Amgen's Otezla.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value